FDA Approved: JANUMET — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

FDA approved a supplemental application for JANUMET (sitagliptin/metformin hydrochloride) filed by Merck Sharp & Dohme LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Janumet (sitagliptin/metformin)

Snippet

SUPPL AP for JANUMET (SITAGLIPTIN AND METFORMIN HYDROCHLORIDE)